Did you miss "Mad Money" on CNBC? If so, here are some of Jim Cramer's top takeaways.

Image placeholder title

In an "Executive Decision" segment, Cramer sat down with JJ Bienaime, CEO of orphan drugmaker BioMarin Pharmaceutical (BMRN) - Get Report , shares of which declined today by 5.6% after the company's analyst day.

Bienaime said they offered an exciting update on their drug portfolio, which now includes six drugs on the market and another three in development. Each of the development drugs could represent a billion dollar opportunity for the company.

Cramer noted that BioMarin is also a terrific drug manufacturer and Bienaime added that they now have four facilities around the world to manufacture their products.

Despite all the healthcare debates here in the U.S., Bienaime said that the U.S. continues to leader the world in biotechnology and he doesn't see that changing any time soon.

Over on Real Money, Cramer says Facebook (FB) - Get Report just made a little-noticed purchase of a highly successful app. Get his insights with a free trial subscription to Real Money.

Cramer and the AAP team say good news is spreading throughout their portfolio. Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

You're Invited

Cramer will host CNBC's Jon Najarian, TD Ameritrade's JJ Kinahan, famed analytics expert Marc Chaikin and other market experts on Oct. 28 in New York City to share successful strategies for active investors.

You can join them as they discuss how smart investors can make the most of options trading, futures contracts, fundamental and quantitative analysis and great ETFs to buy right now. Participants will also get a chance to meet Jim and other panelists.

When: Saturday, Oct. 28, 8 a.m. to 3 p.m.; Where: The Harvard Club of New York, 35 West 44th St., New York; Cost: $250 per person. Click here for the full conference agenda or to reserve your seat now.

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

To read a full recap of this episode of "Mad Money," click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had a position in FB.